Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Sjögren’s Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019The Sjögren’s Syndrome Therapeutics Market is Forecast to Show Steady Growth until 2019
By: GlobalData The current competition in the Sjögren’s syndrome therapeutics market is weak. There is significant opportunity for new entrants that are able to offer a disease-targeting approach. Only two drugs (pilocarpine (brand name Salagen) and cevimeline marketed as Evoxac) are approved for symptomatic relief. Other treatment options include generics, over the counter medication and off-label drugs with low safety profiles. The current therapies only offer symptomatic treatment for Sjögren’s syndrome. New drugs able to reduce the severity or provide a disease-targeting mechanism will be able to successfully capture the Sjögren’s syndrome therapeutics market. GlobalData’s analysis indicates that there will be no significant change in the future landscape of the Sjögren’s syndrome therapeutics market. This is mainly attributed to the weak pipeline with only one company-sponsored First-In-Class (FIC) molecule (P-522-02, developed by Parion Sciences in collaboration with Kainos Medicines) in Phase II. The present competition in the market is weak, as there are no approved drugs that can slow the progression of the disease or treatment options that can cure the disease. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The current market is dominated by the usage of generics, over the counter and off-label medicines, such as Disease-Modifying Antirheumatic Drugs (DMARDS) such as hydroxycholoroquine, cyclosporine A, methotrexate, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) (ibuprofen), salicytes (aspirin), corticosteroids (predinisone, Solbar 50), artificial tears, artificial saliva and other medications. These drugs only provide symptomatic relief. P-522-02 is also expected to provide symptomatic relief and is therefore not expected to impact the market during the forecast period. The product pipeline for the clinical development of Sjögren’s syndrome treatment is weak, with seven molecules in the various phases of development. However, only one of these is sponsored by a company as the rest are all clinical studies sponsored by academic institutions/ GlobalData, the industry analysis specialist, has released its new report, “Sjögren’ For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
|